Heba M Ismail il 02/04/2025

The Disposition Index in Autoantibody-Positive Individuals at Risk for Type 1 Diabetes

Diabetes. 2025 Apr 2:db241000. doi: 10.2337/db24-1000. Online ahead of print.ABSTRACTSince little is known about the disposition index (DI) in autoantibody-positive individuals, we have assessed whether DI has a similar association between insulin secretion and resistance to the association observed

Anika Bilal il 02/04/2025

A Randomized-Controlled, Double-Masked Cross-Over Study of a GPR119 Agonist on Glucagon Counterregulation during Hypoglycemia in Type 1 Diabetes

Diabetes. 2025 Apr 2:db250096. doi: 10.2337/db25-0096. Online ahead of print.ABSTRACTActivation of GPR119 receptors, expressed on enteroendocrine and pancreatic islet cells, augments glucagon counterregulatory responses to hypoglycemia in pre-clinical models. We hypothesized that MBX-2982, a GPR119

Jin Yoo il 28/03/2025

DA-1241, a GPR119 agonist, ameliorates fatty liver through the upregulation of TFEB-mediated autophagy

Diabetes. 2025 Mar 28:db240370. doi: 10.2337/db24-0370. Online ahead of print.ABSTRACTG protein-coupled receptor 119 (GPR119) is predominantly expressed in pancreatic β-cells, enteroendocrine cells, and the liver. It is a novel therapeutic for dyslipidemia and type 2 diabetes. DA-1241, a GPR119 agon

Aijun Jiang il 25/03/2025

Up-regulation of acid-sensing ion channel 1a in the anterior cingulate cortex by TNF-alpha/NF-kappaB pathway contributes to diabetes-related pain

Diabetes. 2025 Mar 25:db240847. doi: 10.2337/db24-0847. Online ahead of print.ABSTRACTEffective treatment strategies for diabetes-related pain are limited due to its complex pathogenesis, particularly brain mechanisms underlying this disease. The acid-sensing ion channel 1a (ASIC1a) emerges as a key

Benjamin Page il 20/03/2025

Diabetes Spotlight: Alice Y.Y. Cheng, MD, FRCPC: Distilling the Complex Language of Clinical Research

No abstractDiabetes. 2025 Apr 1;74(4):453. doi: 10.2337/dbi25-0012.NO ABSTRACTPMID:40112157 | DOI:10.2337/dbi25-0012

Pouria Akhbari il 10/03/2025

Soluble HLA class I is released from human β-cells following exposure to interferons

Diabetes. 2025 Mar 10:db240827. doi: 10.2337/db24-0827. Online ahead of print.ABSTRACTHLA class I (HLA-I) molecules present intracellular antigenic peptides to CD8+ T lymphocytes during immune surveillance. In donors with type 1 diabetes, hyperexpression of HLA-I occurs in islets with residual insul

Jeffrey P Krischer il 10/03/2025

A Comparative Analysis of the Sensitivity, Specificity, Concordance, and the 5-year Predictive Power of Diabetes-related Autoantibody Assays

Diabetes. 2025 Mar 10:db240814. doi: 10.2337/db24-0814. Online ahead of print.ABSTRACTThis study compares novel type 1 diabetes-related autoantibody assays developed to improve upon the standard radiobinding assay (RBA). Samples from 1505 individuals, followed for 5 years or to clinical type 1 diabe

Taylor K Watson il 06/03/2025

Reduced function of the adaptor SH2B3 promotes T1D via altered cytokine-regulated, T cell intrinsic immune tolerance

Diabetes. 2025 Mar 6:db240655. doi: 10.2337/db24-0655. Online ahead of print.ABSTRACTGenome-wide association studies have identified SH2B3 as an important non-MHC gene for islet autoimmunity and type 1 diabetes (T1D). In this study, we found a single SH2B3 haplotype significantly associated with inc

Resham L Gurung il 04/03/2025

Association of plasma angiogenin with risk of incident end-stage kidney disease in individuals with type 2 diabetes

Diabetes. 2025 Mar 4:db240699. doi: 10.2337/db24-0699. Online ahead of print.ABSTRACTWe aim to investigate the association between plasma angiogenin and the risk of progression to end-stage kidney disease (ESKD) in Type 2 Diabetes (T2D) patients and attempted to infer the causal relationship between

Jeongmin Lee il 03/03/2025

Regulation of Type 1 Diabetes via Brown Adipocyte-Secreted Proteins and the Novel Glucagon Regulator Nidogen-2

Diabetes. 2025 Feb 28:db241003. doi: 10.2337/db24-1003. Online ahead of print.ABSTRACTCurrent treatments for type 1 diabetes (T1D) focus on insulin replacement. We demonstrate the therapeutic potential of a secreted protein fraction from embryonic brown adipose tissue (BAT) that mediates insulin rec

Ella A Thomson il 03/03/2025

Intermittent Low-Magnitude Pressure Applied Across Macroencapsulation Devices Enables Physiological Insulin Delivery Dynamics

Diabetes. 2025 Feb 28:db240818. doi: 10.2337/db24-0818. Online ahead of print.ABSTRACTCadaveric islet and stem cell-derived transplantation hold promise as treatments for type 1 diabetes (T1D). To tackle the issue of immunocompatibility, numerous cellular macroencapsulation techniques that utilize d

Shafeeq A Mohammed il 27/02/2025

Targeting SETD7 Rescues Diabetes-induced Impairment of Angiogenic Response by Transcriptional Repression of Semaphorin 3G

Diabetes. 2025 Feb 27:db240997. doi: 10.2337/db24-0997. Online ahead of print.ABSTRACTRevascularization strategies failed to improve outcome in diabetic (DM) patients with peripheral artery disease (PAD). Histone modifications are key modulators of gene expression and could play a role in angiogenic

Chieh-Kai Chan il 25/02/2025

Unilateral Primary Aldosteronism Lacking KCNJ5 Somatic Mutations is Associated with an Elevated Risk of New-Onset Diabetes Mellitus

Diabetes. 2025 Feb 25:db230273. doi: 10.2337/db23-0273. Online ahead of print.ABSTRACTThe association between KCNJ5 mutations and the risk of developing new-onset diabetes mellitus (NODM) in patients with unilateral primary aldosteronism (uPA) remains underexplored. To investigate this association,

Alessandra Granato il 21/02/2025

Metabolic dysfunction associated with alterations in gut microbiota in adolescents with obesity

Diabetes. 2025 Feb 21:db240866. doi: 10.2337/db24-0866. Online ahead of print.ABSTRACTObesity in childhood is associated with adulthood obesity, type 2 diabetes (T2D), and future metabolic complications. The gut microbiome is a modifier of host metabolic function with altered bacterial composition a

Benjamin Page il 20/02/2025

Diabetes Spotlight: Lisa Chow, MD, MS: Quantifiable Lifestyle Changes to Improve Diabetes Outcomes

No abstractDiabetes. 2025 Mar 1;74(3):251. doi: 10.2337/dbi24-0056.NO ABSTRACTPMID:39977619 | DOI:10.2337/dbi24-0056

Josef Finsterer il 20/02/2025

Comment on Chanoine et al. Is Hyperactive mTORC1 Signaling Responsible for the Phenotypic Expression (Diabetes, Hypoacusis) of the m.3243A>G Variant?

No abstractDiabetes. 2025 Mar 1;74(3):e6-e7. doi: 10.2337/db24-1061.NO ABSTRACTPMID:39977618 | PMC:PMC11842563 | DOI:10.2337/db24-1061

Elisabetta Manduchi il 20/02/2025

Response to Comment on Manduchi et al. No Evidence for Persistent Enteroviral B Infection of Pancreatic Islets in Patients With Type 1 Diabetes and Prediabetes From RNA Sequencing Data. Diabetes 2024;73:1697-1704

No abstractDiabetes. 2025 Mar 1;74(3):e5. doi: 10.2337/dbi24-0043.NO ABSTRACTPMID:39977617 | PMC:PMC11842564 | DOI:10.2337/dbi24-0043

Jean-Pierre Chanoine il 20/02/2025

Response to Comment on Chanoine et al. Understanding the Complexity of MIDD Diabetes Mechanism With Dual Focus on beta-Cell Function and Insulin Sensitivity

No abstractDiabetes. 2025 Mar 1;74(3):e8-e9. doi: 10.2337/dbi24-0053.NO ABSTRACTPMID:39977615 | DOI:10.2337/dbi24-0053

Federica Vecchio il 20/02/2025

Comment on Manduchi et al. No Evidence for Persistent Enteroviral B Infection of Pancreatic Islets in Patients With Type 1 Diabetes and Prediabetes From RNA Sequencing Data. Diabetes 2024;73:1697-1704

No abstractDiabetes. 2025 Mar 1;74(3):e3-e4. doi: 10.2337/db24-0809.NO ABSTRACTPMID:39977614 | DOI:10.2337/db24-0809

David A D'Alessio il 20/02/2025

Development of the Insulin Radioimmunoassay, the Watershed Moment in Diabetes Research: Revisiting 1960 Diabetes Classics by Berson and Yalow

Diabetes. 2025 Mar 1;74(3):252-254. doi: 10.2337/dbi24-0055.ABSTRACTThe discovery and development of the radioimmunoassay (RIA) for insulin by Berson and Yalow fundamentally changed biomedical science. The story of this accomplishment began with the pairing of brilliant scientists with complementary

Qin Li il 12/02/2025

Differential Effects of Retinol-Binding Protein 3 and Anti-VEGF Antibodies on Retinal Dysfunctions in Diabetic Retinopathy

Diabetes. 2025 Feb 12:db240822. doi: 10.2337/db24-0822. Online ahead of print.ABSTRACTAnti-vascular endothelial growth factor (anti-VEGF) therapies are effective treatment of severe diabetic retinopathy (DR) and macular edema, but a significant subset of people showed inadequate response to anti-VEG

Yu Wang il 11/02/2025

Comparison of the Effects of SGLT-2i versus GLP-1RA on Cardiovascular and Renal Outcomes in Patients with Type 2 Diabetes Mellitus based on Baseline Renal Function

Diabetes. 2025 Feb 11:db240688. doi: 10.2337/db24-0688. Online ahead of print.ABSTRACTThere remained no head-to-head research to evaluate the cardiovascular and renal benefits of sodium-glucose cotransporter 2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in patients w

Mahircan Yagan il 03/02/2025

Atf4 protects islet β-cell identity and function under acute glucose-induced stress but promotes β-cell failure in the presence of free fatty acid

Diabetes. 2025 Feb 3:db240360. doi: 10.2337/db24-0360. Online ahead of print.ABSTRACTGlucolipotoxicity, caused by combined hyperglycemia and hyperlipidemia, results in β-cell failure and type 2 diabetes via cellular stress-related mechanisms. Activating transcription factor 4 (Atf4) is an essential

Shu Yang il 28/01/2025

Deubiquitinating enzyme USP2 alleviates muscle atrophy by stabilizing PPARγ

Diabetes. 2025 Jan 28:db240375. doi: 10.2337/db24-0375. Online ahead of print.ABSTRACTInsulin resistance, a hallmark of type 2 diabetes, accelerates muscle breakdown and impairs energy metabolism. However, the role of Ubiquitin Specific Peptidase 2 (USP2), a key regulator of insulin resistance, in s